1、2009 ANNUAL REPORTDELIVERING ON OUR COMMITMENTSBristol-Myers Squibb345 Park Avenue New York,NY 10154-0037 212-546-4000 This QR-Code can be read with most standard Smartphone QR-Code Reader Apps.ACME-COVER-2009 BMS AR.indd 13/8/10 4:59 PMcONTENTsLetter to Our StockholdersOur Mission and CommitmentFin
2、ancial ReviewBristol-Myers Squibb LeadershipStockholder InformationON ThE cOvER Gary Smith is a high school athletic director who loves the outdoors.In late 2008,he noticed a suspicious mole on his left shoulder.It was diagnosed as melanoma,the most dangerous form of skin cancer.“I never felt sick,”
3、says Gary,“so it was hard for me to grasp the severity of the illness.”Despite surgery,however,the cancer spread to his lymph nodes,liver and bones.There were few treatment options,so his doctor recommended that he enter a clinical trial for ipilimumab,an investigational biologic in late-stage clini
4、cal development.Bristol-Myers Squibb gained the full rights to ipilimumab through its acquisition of Medarex,Inc.Since entering the trial in April 2009,Gary seems to be doing well.“I havent slowed down,”he says.One lifestyle change,however:“Now I use sunscreen.”Earnings Per Share$1.63$1.35$0.65(from
5、 continuing operations attributable to Bristol-Myers Squibb)200920082007GAAP$1.85$1.49$1.04200920082007Non-GAAPFor further detail on managements use of non-GAAP financial information and reconciliation of non-GAAP to GAAP EPS,see“Managements Discussion and Analysis of Financial Condition and Results
6、 of Operations Non-GAAP Financial Measures”enclosed and the“Quarterly Package of Financial Information”on the companys website at .Cash,Cash Equivalents and Marketable SecuritiesDollars in billions,year ended December 31200920082007$9.9$8.5$2.6FINANCIAL HIGHLIGHTSNet SalesDollars in billions20092008